Spruce Biosciences (NASDAQ:SPRB) Upgraded at Zacks Research

Zacks Research upgraded shares of Spruce Biosciences (NASDAQ:SPRB) from a hold rating to a strong-buy rating in a report released on Thursday,Zacks.com reports.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Spruce Biosciences in a research note on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Spruce Biosciences has a consensus rating of “Hold” and a consensus target price of $131.25.

Spruce Biosciences Stock Up 0.8%

Shares of NASDAQ:SPRB opened at $157.82 on Thursday. The company has a market cap of $88.69 million, a PE ratio of -1.83 and a beta of 2.47. The company’s 50-day moving average price is $39.58 and its 200 day moving average price is $19.39. Spruce Biosciences has a fifty-two week low of $4.28 and a fifty-two week high of $240.00.

About Spruce Biosciences

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.